For instance, the antimalarial drug artinemol targets human proteins that were found to be differentially targeted by IBD cohorts’ microbiomes (in Franzosa et al.): the RNA helicase DDX5, puromycin-sensitive aminopeptidase (NPEPPS), annexin A2 (ANXA2), and the splicing factor SFPQ (Fig.4C, Additional file 7: Table S6). Here, DDX5 is linked to inflammatory bowel disease.